Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1026706 in Diabetic Macular Edema
NCT02732951Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in diabetic macular edema (DME) comparing BI 1026706 with Placebo (2 arms). Primary endpoint: Change From Baseline in Central Subfield Foveal Thickness at 12 weeks. Started Apr 2016; status: completed.
02
Drugs
BI 1026706
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02732951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02732951.